Ipca Laboratories Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xo1ltj25ao63ez45xswta1d2.pdf

Key Takeaways


Domestic Formulation: The Cardiac Disruption

A. K. Jain: "If you don't add too many people, margins will definitely keep on expanding because your productivity keeps on building up."

Unichem: The Consolidated Margin Anchor

Harish Kamath: "What happened, 2-3 products where they were having very good market share and their own API and good margin, they lost business to some competition. So, they have gained market share in other products, but that business has yet to come."

US Business: Early Innings, Two Engines


Export Markets: UK Pain, Rest of World Gain

A. K. Jain: "some of the products were even selling below cost. What has been shipped from India, the sales prices in UK was lower than that."

Subsidiaries & Projects: Investment Phase Continues

A. K. Jain: "I think 2-3 years period is a good, 2 years period is a good number to see that. We scale up all these kind of subsidiaries."

Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated topline growth9%–10% growthFY26 full year
Consolidated EBITDA margin expansion~75 bps increase (revised from 100 bps)FY26 full year
Standalone EBITDA margin expansion1.5% increase in Q1; trend to continueFY26 full year
Unichem EBITDA growthNot possible for FY26 because of Q1FY26 full year
Ipca US product launches4–5 more products launchedFY26 (current financial year)
Ipca US annual launch cadence5–6 products every yearOngoing from FY26
Pisgah injectable commercial readinessCommercially readyH2 FY26
Unichem synergy benefits materialiseAround one year from now~FY27

Key Metrics

MetricQ1 FY26
Standalone revenueNot explicitly stated as a single figure; domestic business grew ~10% YoY
Consolidated revenue growth guidance9%–10% for FY26
Standalone EBITDA margin23.82%, up from 22.22% in Q1 FY25
Consolidated EBITDA margin~18.39%, down from 18.52% in Q1 FY25
Consolidated EBITDA margin guidance~75 bps improvement for FY26, revised from 100 bps
Standalone net profit~₹262 cr, up ~26% YoY
Consolidated net profit~₹234 cr, up ~18% YoY
Standalone gross margin~74%
Domestic formulation growth (IQVIA)11.6%, vs IPM growth of ~8%
Acute segment growth (IQVIA)9.8%, vs industry acute growth of 6.8%
Chronic segment growth (IQVIA)15.1%, vs industry chronic growth of ~9.9%
Branded formulation exports~₹124 cr, up 10% YoY from ~₹113 cr
Generic exports~₹326 cr, up ~15% YoY from ₹283 cr
API business growth~12% YoY
Unichem consolidated revenue growth~9% YoY
Unichem US business growth~12% YoY
Ipca standalone US business annual run-rate visibility$15–$16 million for FY26
Overall market share (IQVIA, mid-June 2025)2.08%, up ~7 bps from 2.01% in mid-June 2024
Cardiovascular therapy growth~8% in Q1
Pain management therapy growth~13% in Q1
MR additions in cardiovascular~400 people added
Total salesforceJust over 7,000 people
Onyx Scientific Q1 loss~£300,000
Unichem additional provision (currency fluctuation on EU penalty)~₹12 cr
Unichem Ireland facility closure redundancy cost~₹8–₹10 cr
Unichem Asia business (Myanmar impact)Declined from ₹23 cr to ~₹8 cr
Unichem Brazil businessDeclined from ₹21 cr to ~₹14 cr
Unichem European business~₹36 cr, up ~37% from ₹26 cr
Ipca US products launched4 products launched; another 4–5 expected in FY26
Ipca US products under development~15–16 products